# Do People Fill Their GLP-1 Prescriptions? What Pharmacy Records Show

Compare documented first fills, prescription denials and treatment discontinuation across GLP-1 studies, with the population and time window for each result.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/do-people-actually-fill-a-glp1-prescription
Updated: 2026-11-15
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# Do People Fill Their GLP-1 Prescriptions? What Pharmacy Records Show

In one U.S. health system, about seven in ten patients with a new GLP-1 prescription had a documented fill within 30 days.

Editorial profile: [Neil Sanders](https://buythisglp.com/authors/neil-sanders)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20265 min readUpdated November 2026

New GLP-1 prescriptions at one health system · 70.2% documented fill · 29.8% no documented fill within 30 days

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   In one U.S. health system, 70.2% of patients with a new GLP-1 prescription had a documented fill within 30 days.
-   A separate study found 60.1% of Colorado GLP-1 orders matched a pharmacy fill within 90 days. It counted both initial orders and refills.
-   An insurance denial, an unfilled prescription and stopping a drug after a fill are different outcomes.

## How many people filled a new GLP-1 prescription?

In one integrated U.S. health system, 726 of 2,435 patients (29.8%) with a new GLP-1 prescription from 2012 through 2019 had no documented pharmacy fill for a drug in that class within 30 days. That means 70.2% had a documented fill. The records could miss a fill paid in cash outside the health plan [\[1\]](https://buythisglp.com/research/do-people-actually-fill-a-glp1-prescription#ref-1).

A Colorado study linked records for 9,848 orders and 6,094 patients enrolled in Medicare or commercial insurance between 2018 and 2022. Within 90 days, 60.1% of the orders had a recorded fill. That study counted initial orders and refill orders, and the rate varied by indication: 37.2% for obesity alone, 47.5% for diabetes alone and 64.6% for both [\[2\]](https://buythisglp.com/research/do-people-actually-fill-a-glp1-prescription#ref-2). Those figures describe the cohort. The [GLP-1 insurance coverage guide](https://buythisglp.com/research/does-insurance-cover-glp1) explains how coverage rules can vary by diagnosis and plan.

## What happens after an insurance denial?

The steps in [GLP-1 prior authorization](https://buythisglp.com/research/how-long-does-prior-authorization-take-for-a-glp1) can affect when a pharmacy can bill a plan. In separate national claims data from 2018 through 2024, 34.1% of 173,782 people with a first observed denied claim and enough follow-up had a paid GLP-1 fill within 90 days. The data did not identify whether each denial reflected prior authorization, a formulary exclusion, step therapy or another reason [\[3\]](https://buythisglp.com/research/do-people-actually-fill-a-glp1-prescription#ref-3).

In the 2022 Medical Expenditure Panel Survey, adults with type 2 diabetes and above-median income had higher odds of semaglutide use (OR 1.61, 95% CI 1.14 to 2.26). Private insurance was also associated with higher odds (OR 1.52, 95% CI 1.04 to 2.22). The survey measured use, so it cannot tell us the share of written prescriptions people filled [\[5\]](https://buythisglp.com/research/do-people-actually-fill-a-glp1-prescription#ref-5).

## What a two-drug trial adds

The PRECIDENTD feasibility report followed 173 adults with type 2 diabetes and cardiovascular disease or elevated cardiovascular risk. Nearly all had insurance. Participants were randomized to a GLP-1 receptor agonist, an SGLT2 inhibitor, or both. Within four months, 84% of those assigned either single drug reported obtaining it, compared with 53% assigned both who reported obtaining both. During median follow-up of ten months, those figures reached 87% and 68% [\[4\]](https://buythisglp.com/research/do-people-actually-fill-a-glp1-prescription#ref-4).

Among those who obtained all assigned study medicines, 22% in the pooled single-drug group and 49% in the two-drug group stopped at least one, most often because of side effects. The study pooled two different single-drug groups and included participants already taking a GLP-1 at enrollment. It did not estimate a general first-fill rate for GLP-1 medicines or report the main trial’s long-term cardiovascular and kidney outcomes [\[4\]](https://buythisglp.com/research/do-people-actually-fill-a-glp1-prescription#ref-4).

## What happens after the first fill?

Studies measuring [how long people stay on a GLP-1](https://buythisglp.com/research/how-long-do-people-stay-on-a-glp1) start counting after the first fill. In one Kaiser Permanente Colorado cohort, 436 of 1,374 adults (31.7%) who first filled semaglutide or liraglutide between 2018 and 2023 stopped within 180 days. Among those who stopped, an adverse drug reaction was documented for 26.8% and a cost concern for 14.4%. The adjusted odds of stopping were higher for those with overweight or obesity alone than for those with both diabetes and overweight or obesity (OR 2.46, 95% CI 1.17 to 5.17) [\[6\]](https://buythisglp.com/research/do-people-actually-fill-a-glp1-prescription#ref-6).

If cost affects whether you fill or refill, the guide to [monthly GLP-1 costs](https://buythisglp.com/research/how-much-does-a-glp1-cost-per-month) explains which charges to confirm with the pharmacy or plan before comparing the first fill with later refills.

## Frequently asked

How many people fill a new GLP-1 prescription?

In one U.S. health system, 70.2% of 2,435 patients newly prescribed a GLP-1 had a documented fill for a drug in the same class within 30 days. That study used 2012–2019 records and could miss cash fills outside the health plan.

Does an insurance denial mean a prescription will never be filled?

In a national claims study, 34.1% of people with a first observed denied GLP-1 claim and enough follow-up eventually had a paid GLP-1 fill within 90 days. The data cannot tell whether the first claim was reversed or a different GLP-1 was filled.

How many people stopped after filling?

In one Kaiser Permanente Colorado cohort, 31.7% of 1,374 adults who filled semaglutide or liraglutide stopped within 180 days. Adverse drug reactions and concerns about cost were among the documented reasons.

## Sources

1.  \[1\] Luo J, et al. (2022). Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System Journal of General Internal Medicine. [PMID 35048301](https://pubmed.ncbi.nlm.nih.gov/35048301/)
2.  \[2\] Sarpatwari A, Soto MJ, Ganguli I, Sloan CE, Goss F, Sinaiko AD (2025). Glucagon-Like Peptide-1 Receptor Agonist Order Fills and Out-of-Pocket Costs by Race, Ethnicity, and Indication JAMA Health Forum. [Source](https://pmc.ncbi.nlm.nih.gov/articles/PMC12514621/)
3.  \[3\] Jia M, et al. (2026). Prescription denials for GLP-1 receptor agonists across commercial, Medicare, and Medicaid coverage, 2018-2024 Health Affairs Scholar. [PMID 42948647](https://academic.oup.com/healthaffairsscholar/article/4/10/qxag284/8922286)
4.  \[4\] Wexler DJ, et al. (2026). Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial American Heart Journal. [PMID 41456635](https://pubmed.ncbi.nlm.nih.gov/41456635/)
5.  \[5\] Vaidya V, et al. (2026). Income disparities and accessibility to Semaglutide: implications for diabetes management and policy reform International Journal for Quality in Health Care. [PMID 41437637](https://pubmed.ncbi.nlm.nih.gov/41437637/)
6.  \[6\] Van Laren J, et al. (2026). Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist Diabetes, Obesity and Metabolism. [PMID 41713959](https://pubmed.ncbi.nlm.nih.gov/41713959/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
